Blaine Labs recalled certain Revitaderm® and Tridergel™ antiseptic wound care gel due to contamination with bacteria called Lysinibacillus fusiformis. If you were treated at a doctor’s office with one of these gels and later developed a wound infection or other complication, it was not your fault.
What You Can Do & How We Can Help
The Schmidt Firm, PLLC is currently accepting contaminated wound care gel cases in all 50 states. If you were treated with recalled Revitaderm® or Tridergel™ wound care gel at a physician clinic and suffered an infection, delayed wound healing, or other injury, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Product Recall Litigation Group or call toll free 24 hours a day at (866) 920-0753.
About the Blaine Labs Wound Care Gel Recall
In April 2026, Blaine Labs, Inc. of Santa Fe Springs, California announced a recall of 3 lot numbers of its Revitaderm® Wound Care Antiseptic Gel (1 oz. and 3 oz.) and Tridergel™ Wound Care (1 oz.). The recall was announced after testing identified contamination with Lysinibacillus fusiformis, an environmental, spore-forming bacterium.
Which Products Were Recalled?
The following lot numbers are included in the recall:
- Revitaderm® Wound Care Antiseptic Gel 1 oz. — Lot BL3608 (Exp. 07/01/28), shorter twist cap; Lot BL3435 (Exp. 11/06/26), long pointy cap; Lot BL3525 (Exp. 08/07/27), long pointy cap
- Revitaderm® Wound Care Antiseptic Gel 3 oz. — Lot BL3435 (Exp. 11/06/26); Lot BL3525 (Exp. 08/07/27)
- Tridergel™ Wound Care 1 oz. — Lot BL3435 (Exp. 11/06/26), long pointy cap
Revitaderm® is identified by purple trim. Tridergel™ is identified by light blue trim. The lot number and expiration date appear on the bottom of 1 oz. bottles and along the crimp of 3 oz. tubes.
Where Were the Recalled Products Distributed?
The recalled wound care gels were distributed exclusively to healthcare providers, specifically physician clinics and doctor’s offices, nationwide. They were not sold through retail stores or over the internet.
This means that potential victims are patients who received treatment at a clinic or doctor’s office where one of the recalled wound gels were being used.
What Is the Risk of Lysinibacillus fusiformis Contamination?
According to Blaine Labs’ own risk statement, Lysinibacillus fusiformis is generally considered to have low pathogenicity in healthy individuals. However, the company acknowledges that patients with open wounds, compromised skin barriers, or weakened immune systems may be at increased risk. The recall warns:
“While it is generally considered to have low pathogenicity in healthy individuals, it can survive in adverse conditions and may act as an opportunistic organism.”
What People Have the Highest Risk of Infection?
Blaine Labs specifically identifies the following high-risk groups:
- Elderly individuals with age-related immune decline
- Diabetic patients with poorly controlled diabetes
- Young children with an immature immune system
- Immunocompromised individuals of any age
For the highest-risk patients, the company warns that infections may become severe and lead to life-threatening complications, including endocarditis or central nervous system infection.
Have Any Injuries Been Reported?
As of the recall announcement date of April 7, 2026, Blaine Labs reported that no adverse events had been received in connection with these lot numbers. However, the recall was issued as a precautionary measure and the underlying contamination is confirmed.
What Should Patients and Healthcare Providers Do?
Healthcare providers holding any of the recalled lot numbers should discontinue use and distribution immediately, segregate remaining inventory, and contact Blaine Labs to arrange for return.
Patients who believe they were treated with one of the recalled products can contact Blaine Labs at (800) 307-8818, Monday through Friday, 7:30 AM to 4:00 PM PST, or by email at Contact@blainelabs.com. Adverse reactions may also be reported to the FDA’s MedWatch program.
Legal Options for Patients Harmed by Contaminated Wound Care Products
When a company distributes a contaminated antiseptic product intended for use on open wounds, patients who suffer infections as a result may have legal claims against the manufacturer. Patients treated with the recalled Blaine Labs wound care gel who developed wound infections, skin complications, or more serious illness may be entitled to compensation for medical bills, pain and suffering, and other damages.
Product liability laws hold manufacturers to a high standard — especially when contaminated products are applied directly to vulnerable patients. Time limits apply to these claims, so do not wait to explore your options.
Free Consultation — No Fee Unless You Win
The Schmidt Firm, PLLC is investigating cases for people harmed by recalled wound care products. If you were treated at a physician clinic with recalled Revitaderm® or Tridergel™ wound care gel and experienced complications, contact our lawyers today for a free case review. Call us 24 hours a day at (866) 920-0753.
—
⚠️ CASE VIABILITY NOTE FOR USER: This recall has some characteristics that may affect case volume:
(1) Products were distributed ONLY to healthcare providers, not retail — potential claimants are clinic patients, not general consumers.
(2) No adverse events have been reported as of the recall date.
(3) Lysinibacillus fusiformis has low pathogenicity in healthy individuals — the risk is concentrated in immunocompromised, elderly, and diabetic patients.
Cases may be viable for high-risk patients who developed documented infections or complications after being treated at a clinic. This may be a lower-volume but real case type. You may want to hold publishing until adverse event reports surface.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
